Anemia (low hemoglobin content) is a serious side effect of their triple combo.
[The most common adverse events were headache, fatigue, upper respiratory tract infection and nausea. The most common clinically significant grade 3/4 laboratory abnormality was a hemoglobin reduction.]
Third... How is it that in AF's article today about the hep C trials there is no mention of the failure of 7977 in so many of the elctron study arms and that the SVR 4 reuslts for the 25 patient arm that did well in treatment naive two drug combination could relapse like the 7977 arm plus riba arms did in most of the study arms at 24 weeks post treatment?
Q, I have done some research after reading your post. An EASL 2012 slide clearly stated a 10 subject ELECTRON arm achieved 100% of SVR12 against HCV GT2/3. The arm was also treating for 8 weeks.
This 10 patient arm could be distinct from the arm for which they reported today. Either one is very wrong. They did not explain this discrepancy in today's report.
Today's report is closer to the truth because they are abandoning the 8 wk treatment regimen in favor of a 12 wk regimen for the GT2/3 Phase III. I also found a good amount of relapses between EOT and Week 4 and between Week 4 and Week 12 by comparing the AASLD abstract and today's report.